From the Divisions of Nuclear Medicine and Molecular Imaging, and.
Endocrinology, Stanford University, Stanford, CA.
Clin Nucl Med. 2018 Oct;43(10):705-709. doi: 10.1097/RLU.0000000000002246.
The use of I whole body scintigraphy (WBS) before I radioiodine ablation (RIA) of the post-surgical thyroid remnant in patients with papillary thyroid cancer (PTC) remains debated. The American Thyroid Association's guidelines state that WBS may be useful before RIA (rating C-expert opinion). Some institutions do not use I WBS before RIA in their routine clinical protocol. We were therefore prompted to evaluate the impact of I WBS prior to ablation of thyroid remnant in patients with PTC.
We reviewed data from 152 consecutive patients with PTC who had total thyroidectomy and were referred for RIA between August 2007 and February 2009 at our institution. The group included 107 women and 45 men, 13-82 years old (mean ± SD: 45.5 ± 18.3). Three endocrinologists blinded to the results of the I WBS reviewed patients' data including sex, age, pathology, thyroglobulin (Tg) level, anti-Tg antibodies, thyroid stimulating hormone (TSH) level and ultrasound results. Each endocrinologist then returned a form with the recommended I dose for each participant, according to the following rules: 50-75 mCi (remnant ablation), 75-125 mCi (lymph nodes metastases), 150 mCi (lung metastases), and 200 mCi (bone metastases). We compared their recommended doses with the actual I doses prescribed after the pre-therapy I WBS.
All three endocrinologists recommended the same dose in 98.7% of the cases. The dose prescribed by the endocrinologists matched the dose administered after analyzing the I WBS in 77 patients (51%). However, for 46 patients (30%) the endocrinologists would have given a lower dose, for 18 patients (12%) a higher dose than that administered based on the results of the I WBS, while 11 patients (7%) would have been treated unnecessarily (5/11 had no I uptake and 6/11 had I uptake in the breasts).
Our study suggests a significant role of the pre-therapy I WBS in PTC patients referred for I ablation post-thyroidectomy. The actual I dose that was administered based on the I WBS differed from the dose recommended in the absence of the I WBS in 49% of the cases.
甲状腺癌患者在接受放射性碘消融术(RIA)治疗甲状腺残体之前,全身碘扫描(I WBS)的应用仍存在争议。美国甲状腺协会的指南指出,I WBS 可能对 RIA 有用(评级 C-专家意见)。一些机构在其常规临床方案中不常规进行 I WBS 检查。因此,我们评估了 I WBS 在甲状腺癌患者甲状腺残体消融前的影响。
我们回顾了 2007 年 8 月至 2009 年 2 月期间在我院接受全甲状腺切除术并转至我院接受 RIA 的 152 例连续 PTC 患者的数据。该组包括 107 名女性和 45 名男性,年龄 13-82 岁(平均±标准差:45.5±18.3)。三位内分泌学家对 I WBS 的结果不知情,他们对患者的数据进行了审查,包括性别、年龄、病理学、甲状腺球蛋白(Tg)水平、抗 Tg 抗体、甲状腺刺激激素(TSH)水平和超声结果。每位内分泌学家根据以下规则,为每位参与者制定了 I 推荐剂量,并填写了一张表格:50-75 mCi(残体消融)、75-125 mCi(淋巴结转移)、150 mCi(肺转移)和 200 mCi(骨转移)。我们比较了他们的推荐剂量与 I WBS 治疗前的实际 I 剂量。
在 98.7%的病例中,三位内分泌学家推荐了相同的剂量。在分析了 77 例患者的 I WBS 后,内分泌学家开出的剂量与所给予的剂量相匹配(51%)。然而,在 46 例患者(30%)中,内分泌学家开出的剂量低于根据 I WBS 结果开出的剂量,在 18 例患者(12%)中开出的剂量高于根据 I WBS 结果开出的剂量,而 11 例患者(7%)开出的剂量是不必要的(5/11 例无 I 摄取,6/11 例 I 摄取在乳房中)。
我们的研究表明,I WBS 在甲状腺癌患者术后接受 I 消融治疗前具有重要作用。根据 I WBS 结果给予的实际 I 剂量与在没有 I WBS 的情况下推荐的剂量在 49%的情况下存在差异。